Loading...
XTAE
REKA
Market cap43mUSD
May 22, Last price  
1,377.00ILS
1D
0.00%
1Q
-6.13%
Jan 2017
-34.02%
Name

Rekah Pharmaceutical Industry Ltd

Chart & Performance

D1W1MN
P/E
2,532.70
P/S
48.86
EPS
0.54
Div Yield, %
—
Shrs. gr., 5y
0.89%
Rev. gr., 5y
10.36%
Revenues
322m
+0.02%
269,998,000270,032,000216,372,000262,429,000218,385,000208,184,000207,829,000196,499,000265,473,000263,950,000292,394,000321,663,000321,712,000
Net income
6m
P
7,403,0008,320,000-501,000-4,414,000-11,000,000-22,480,0007,027,0002,755,00010,797,0006,624,000-2,043,000-6,910,0006,206,000
CFO
27m
-6.38%
14,182,00011,706,0001,330,0005,806,00022,825,00023,797,00017,284,00033,913,00011,283,00021,169,00039,002,00028,350,00026,541,000
Dividend
Apr 06, 202286.776 ILS/sh

Profile

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.
URL
https://www.rekah.co.il/
IPO date
Dec 14, 1995
Employees
399
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
321,712
0.02%
321,663
10.01%
292,394
10.78%
Cost of revenue
269,691
316,280
229,537
Unusual Expense (Income)
NOPBT
52,021
5,383
62,857
NOPBT Margin
16.17%
1.67%
21.50%
Operating Taxes
1,722
138
2,400
Tax Rate
3.31%
2.56%
3.82%
NOPAT
50,299
5,245
60,457
Net income
6,206
-189.81%
(6,910)
238.23%
(2,043)
-130.84%
Dividends
(10,000)
Dividend yield
5.69%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
36,834
30,055
25,160
Long-term debt
138,311
194,499
172,352
Deferred revenue
Other long-term liabilities
24,607
36,505
15,346
Net debt
166,934
204,034
177,224
Cash flow
Cash from operating activities
26,541
28,350
39,002
CAPEX
(8,692)
(11,489)
(7,482)
Cash from investing activities
15,286
(21,499)
(13,449)
Cash from financing activities
(54,134)
(7,783)
(24,356)
FCF
81,975
4,649
93,634
Balance
Cash
7,067
19,349
20,288
Long term investments
1,144
1,171
Excess cash
4,437
5,668
Stockholders' equity
34,881
29,478
35,973
Invested Capital
320,738
366,553
325,378
ROIC
14.64%
1.52%
17.81%
ROCE
15.96%
1.45%
18.83%
EV
Common stock shares outstanding
11,415
11,415
Price
13.40
-9.34%
14.78
-3.96%
15.39
-33.89%
Market cap
168,708
-3.96%
175,671
-33.89%
EV
372,790
352,945
EBITDA
84,680
35,220
90,338
EV/EBITDA
10.58
3.91
Interest
6,709
5,646
Interest/NOPBT
12.90%
8.98%